螺内酯联合ACEI治疗COPD合并慢性肺源性心脏病疗效分析

Analysis of Spironolactone Combined with ACEI in the Treatment of Severe COPD Combined with Chronic Pulmonary Heart Disease

目的:总结分析螺内酯联合血管紧张素转换酶抑制剂(ACEI)在重度慢性阻塞性肺疾病(COPD)慢性肺源性心脏病患者临床治疗中的治疗效果。方法:90例重度COPD合并慢性肺源性心脏病患者随机分为观察组和对照组,各45例,对照组给予抗炎、解痉平喘、化痰、氧疗等常规对症治疗,观察组在对照组基础上给予螺内酯片联合ACEI治疗,4周后比较两组患者疗效差异。结果:观察组治疗总有效率明显高于对照组。结论:对于重度COPD合并慢性肺源性心脏患者应用螺内酯联合ACEI进行治疗,能有效提高疗效和改善肺功能。

Objective： To summarize and analyze the treatment effect of spironolactone combined with angiotensin converting enzyme inhibitor（ACEI） in severe chronic obstructive pulmonary disease（COPD） in chronic pulmonary heart disease in clinical treatment. Methods：90 patients with severe COPD combined with chronic pulmonary heart disease patients were randomly divided into observation group and control group, 45 cases in each, control group was given routine symptomatic treatment of anti-inflammatory, relieving asthma, eliminating phlegm, oxygen therapy and so on, while the observation group was given spironolactone tablets combined with ACEI treatment group on the basis of control. After 4 weeks of efficacy of the two groups were compared differences. Results： The total effective rate of the observation group was significantly higher than that of the control group. Conclusion： For severe COPD combined with chronic pulmonary heart patients treated with spironolactone combined with ACEI treatment can effectively improve the curative effect and improve lung function.